
Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,’ analysts say
18.18BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US64125C1099
CUSIP
64125C109
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
27.77
PEG Ratio
0.51
Book Value
33.87
Dividend Share
-
Dividend Yield
-
Earnings Share
6.68
Wall Street Target Price
202.39
EPS Estimate Current Year
9.93
EPS Estimate Next Year
12.52
EPS Estimate Current Quarter
1.7305
EPS Estimate Next Quarter
2.0273
Most Recent Quarter
-
Revenue TTM
3,102,400,000
Gross Profit TTM
1,996,999,936
EBITDA
828,600,000
Profit Margin
21.55%
Return On Assets TTM
11.62%
Return On Equity TTM
22.50%
Revenue Per Share TTM
31.117
Qtly Revenue Growth YOY
42.20%
Diluted Eps TTM
6.68
Qtly Earnings Growth YOY
2310.50%
Trailing PE
27.77
Forward PE
25
Price Sales TTM
6.0121
Price Book MRQ
5.335
Enterprise Value Revenue
5
Enterprise Value EBITDA
20
45.10
4.37%84.07
2.29%169.12
1.73%225.00
0.65%32.96
0.15%28.40
0.00%32.53
-6.90%9.87
-2.37%34.59
-2.27%17.14
-0.28%